Dalton Greiner Hartman Maher & Co Has Raised By $1.04 Million Its Huttig Bldg Prods Com (HBP) Holding; Last Week MorphoSys AG (ETR:MOR) Analysts

September 7, 2017 - By Richard Conner

Dalton Greiner Hartman Maher & Co increased Huttig Bldg Prods Inc Com (HBP) stake by 70.22% reported in 2016Q4 SEC filing. Dalton Greiner Hartman Maher & Co acquired 173,700 shares as Huttig Bldg Prods Inc Com (HBP)’s stock rose 9.91%. The Dalton Greiner Hartman Maher & Co holds 421,074 shares with $2.78 million value, up from 247,374 last quarter. Huttig Bldg Prods Inc Com now has $151.35 million valuation. The stock increased 2.09% or $0.12 during the last trading session, reaching $5.85. About shares traded. Huttig Building Products Inc (NASDAQ:HBP) has risen 56.40% since September 7, 2016 and is uptrending. It has outperformed by 39.70% the S&P500.

Among 8 analysts covering MorphoSys (ETR:MOR), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. MorphoSys had 31 analyst reports since July 27, 2015 according to SRatingsIntel. On Wednesday, August 31 the stock rating was upgraded by Commerzbank to “Buy”. The stock of MorphoSys AG (ETR:MOR) has “Buy” rating given on Friday, March 4 by Independent Research. The firm has “Buy” rating by Independent Research given on Tuesday, February 16. The company was maintained on Tuesday, March 7 by Goldman Sachs. The rating was upgraded by Oddo & Cie to “Buy” on Tuesday, July 28. Independent Research maintained it with “Hold” rating and €48 target in Saturday, April 23 report. The stock of MorphoSys AG (ETR:MOR) has “Hold” rating given on Wednesday, March 2 by Commerzbank. HSBC maintained MorphoSys AG (ETR:MOR) on Friday, July 8 with “Hold” rating. The rating was upgraded by Baader Wertpapierhandelsbank to “Buy” on Thursday, September 24. Commerzbank upgraded the stock to “Buy” rating in Friday, April 8 report. See MorphoSys AG (ETR:MOR) latest ratings:

About 119,936 shares traded. MorphoSys AG (ETR:MOR) has 0.00% since September 7, 2016 and is . It has underperformed by 16.70% the S&P500.

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The company has market cap of 1.92 billion EUR. The Firm develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. It currently has negative earnings. The Company’s operating divisions include Proprietary Development and Partnered Discovery.

Since March 16, 2017, it had 0 insider purchases, and 1 sale for $402,142 activity. 49,999 shares valued at $402,142 were sold by VRABELY JON P on Thursday, March 16.